Clinical Trials Using Glutaminase Inhibitor CB-839

Clinical trials are research studies that involve people. The clinical trials on this list are studying Glutaminase Inhibitor CB-839. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

    This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced / metastatic solid tumors.
    Location: 6 locations

  • A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

    This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4 / 6 Inhibitor, palbociclib in participants with advanced / metastatic solid tumors.
    Location: 6 locations

  • KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1 / NRF2-Mutated, Nonsquamous NSCLC

    This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1 / NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are PFS per RECIST v. 1.1 and safety. KEAP1 / NRF2 mutation status (for eligibility) and STK11 / LKB1 status (for stratification) will be determined by next generation sequencing. A commercial liquid biopsy (circulating tumor DNA) NGS test will be provided to study participants free of charge.
    Location: 3 locations

  • Glutaminase Inhibitor CB-839, Panitumumab, and Irinotecan Hydrochloride in Treating Patients with Metastatic and Refractory RAS Wildtype Colorectal Cancer

    This phase I / II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride in treating patients with RAS wildtype colorectal cancer that has spread to other places in the body and does not respond to treatment. Glutaminase inhibitor CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving glutaminase inhibitor CB-839 with panitumumab and irinotecan hydrochloride may work better in treating patients with colorectal cancer.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients with Advanced Myelodysplastic Syndrome

    This phase I / II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. Glutaminase inhibitor CB-839 and azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Glutaminase Inhibitor CB-839 and Capecitabine in Treating Patients with Advanced Solid Tumors or Colorectal Cancer

    This phase I / II trial studies the side effects and best dose of glutaminase inhibitor CB-839 and capecitabine and to see how well they work in treating patients with solid tumors that have spread to other places in the body or colorectal cancer. Glutaminase inhibitor CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Capecitabine may kill tumor cells by inhibiting deoxyribonucleic acid and ribonucleic acid synthesis. Giving glutaminase inhibitor CB-839 and capecitabine together may work better in treating patients with solid tumors or colorectal cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio